Evidence map›Paper›PMID 22785050›Full record

ReviewJournal of human hypertension2013

Salt, aldosterone and hypertension.

E Pimenta, R D Gordon, M Stowasser

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of human hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Primary aldosteronism.Nature reviews. Disease primers · 2026
    Review
  3. Article
  4. Article
  5. Mechanisms of Post-critical Illness Cardiovascular Disease.Frontiers in cardiovascular medicine · 2022
    Review
  6. Review
  7. Article
  8. Epithelial Sodium Channel and Salt-Sensitive Hypertension.Hypertension (Dallas, Tex. : 1979) · 2021
    Review
  9. [Hyperaldosteronism].Der Internist · 2021
    Review
  10. Observational
  11. Apneic Sleep, Insufficient Sleep, and Hypertension.Hypertension (Dallas, Tex. : 1979) · 2019
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

E PimentaEndocrine Hypertension Research Centre, University of Queensland School of Medicine, Princess Alexandra and Greenslopes Hospitals, Brisbane, Queensland, Australia.
R D Gordon
M Stowasser
University of Queensland · AUGreenslopes Private Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical studies have shown that aldosterone and salt are independently related to hypertension, cardiovascular morbidity and mortality. More recently, studies in humans have demonstrated that, similarly to animals, endogenous aldosterone and dietary salt intake have not only separate, but also combined effects to accelerate target-organ deterioration. The aldosterone-salt interaction has important clinical implications, because combined effects of both can be minimized, if not avoided, by reducing salt intake. This interaction could also be interrupted by blocking the effects of aldosterone, with use of mineralocorticoid receptor antagonists, or by reducing aldosterone effects by adrenalectomy, in patients with aldosterone producing adenoma. Furthermore, aldosterone reduction or blockade may reduce salt appetite.

Indexed as

AldosteroneAnimalsAppetiteCardiovascular DiseasesHumansHyperaldosteronismHypertensionKidney DiseasesSodium Chloride, DietaryAldosteroneSodium Chloride, Dietary

Identifiers

PMID22785050
OpenAlexW2002722423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.